Recent advancements in stem cell technology open a new door for patients suffering from
diseases and disorders that have yet to be treated. Stem cell-based therapy, including …

Ageing and chronic degenerative pathologies demonstrate the shared characteristics of
high bioavailability of reactive oxygen species (ROS) and oxidative stress, chronic/persistent …

Expectations on mesenchymal stem cell (MSC) treatment are high, especially in the fields of
sepsis, transplant medicine, and autoimmune diseases. Various pre-clinical studies have …

The number of clinical trials using mesenchymal stem cells (MSCs) has increased since
2008, but this trend slowed in the past several years and dropped precipitously in 2018 …

Mesenchymal stem cells (MSCs) are isolated from multiple biological tissues—adult bone
marrow and adipose tissues and neonatal tissues such as umbilical cord and placenta. In …

Reconstruction of bone defects, especially the critical-sized defects, with mechanical
integrity to the skeleton is important for a patient's rehabilitation, however, it still remains …

Mesenchymal stem/stromal cells (MSCs) are a promising resource for cell-based therapy
because of their high immunomodulation ability, tropism towards inflamed and injured …

Osteoporosis is a systemic metabolic bone disease with characteristics of bone loss and
microstructural degeneration. The personal and societal costs of osteoporosis are …

To dissect therapeutic mechanisms of transplanted stem cells and develop exosome-based
nanotherapeutics in treating autoimmune and neurodegenerative diseases, we assessed …

Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal
stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has …